Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
boston blog main
boston top stories
eli lilly
6
×
life sciences
6
×
national blog main
new york blog main
new york top stories
san francisco blog main
san francisco top stories
6
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
fda
teva pharmaceutical
crispr
deals
fremanezumab
migraine
novartis
amgen
calcitonin gene-related peptide
cancer
cancer immunotherapy
What
new
6
×
bio
approval
companies
drug
roundup
class
drugs
fda
medicines
migraine
pharmaceutical
won
amgen
arguments
bails
bets
big
biogen’s
biopharma
biopharmaceutical
brand
bridgebio
cancer
candidates
capital
car
comes
commercialized
competitors
congress
congressional
convo
crispr
cut
date
deal
decades
develop
developed
Language
unset
Current search:
new
×
photo
×
" life sciences "
×
" eli lilly "
×
" san francisco top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
6 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines